secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001104659-26-040673
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical receives FDA IDE approval to study next-gen vCLAS ventricular ablation system
--------------------------------------------------------------------------------

- FDA grants IDE approval to expand FULCRUM-VT trial for next-gen vCLAS ULTA Ventricular Ablation System treating SMVT.
- System achieves ~ -170°C for single-freeze lesions with >50% reduction in ablation time vs prior models.
- Prospective, single-arm, multi-center sub-study of up to 55 patients for scar-mediated SMVT.
- Next-gen vCLAS Ultra catheter designed for improved maneuverability, shorter freeze times, and scalability.
- Goal is a single versatile catheter treating full VT range via endocardial approach on established ULTA platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000110465926040673/0001104659-26-040673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000110465926040673/tm2611362d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer